Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double‐blind, multicentre study

Identifieur interne : 001469 ( Main/Exploration ); précédent : 001468; suivant : 001470

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double‐blind, multicentre study

Auteurs : M. Choo [Corée du Sud] ; J. Z. Lee [Corée du Sud] ; J. B. Lee [Corée du Sud] ; Y. Kim [Corée du Sud] ; H. C. Jung [Corée du Sud] ; K. Lee [Corée du Sud] ; J. C. Kim [Corée du Sud] ; J. T. Seo [Corée du Sud] ; J. Paick ; H. Kim [Corée du Sud] ; Y. G. Na [Corée du Sud] ; J. G. Lee [Corée du Sud]

Source :

RBID : ISTEX:09A500C4C70E8A462DC009A9C386CA27B81C751D

Abstract

Purpose:  We assessed the efficacy and safety of solifenacin compared with tolterodine for treatment of overactive bladder (OAB) in Korean patients. Materials and methods:  The study was randomised, double‐blind, tolterodine‐controlled trial in Korea. Patients had average frequency of ≥ 8 voids per 24 h and episodes of urgency or urgency incontinence ≥ 3 during 3‐day voiding diary period. Patients were randomised to 12‐week double‐blind treatment with either tolterodine immediate release (IR) 2 mg twice daily (TOL4) or solifenacin 5 mg (SOL5) or 10 mg (SOL10) once daily. The outcome measure was mean change in daily micturition frequency, volume, daily frequency of urgency incontinence, urgency and nocturia from baseline to week 12. Quality of life was assessed using the King’s Health Questionnaire. Results:  A total of 357 were randomised and 329 were evaluated for efficacy. All voiding parameters recorded in micturition diary improved after treatment in all three groups. Mean changes in volume voided were 19.30 ml (26.69%) in TOL4, 30.37 ml (25.89%) in SOL5 and 37.12 ml (33.36%) in SOL10 group (p = 0.03). Speed of onset of SOL10 efficacy on urgency incontinence was faster than that of SOL5 and TOL4. Quality of life improved in all three groups. Dry mouth was the most common adverse event; its incidence was the lowest in SOL5 group (7.63%, compared with 19.49% and 18.64% in SOL10 and TOL4 groups respectively). Conclusions:  Solifenacin succinate 5 and 10 mg once daily improve OAB symptoms with acceptable tolerability levels compared with tolterodine IR 4 mg. Solifenacin 5 mg is a recommended starting dose in Korean patients with OAB.


Url:
DOI: 10.1111/j.1742-1241.2008.01898.x


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double‐blind, multicentre study</title>
<author>
<name sortKey="Choo, M" sort="Choo, M" uniqKey="Choo M" first="M." last="Choo">M. Choo</name>
</author>
<author>
<name sortKey="Lee, J Z" sort="Lee, J Z" uniqKey="Lee J" first="J. Z." last="Lee">J. Z. Lee</name>
</author>
<author>
<name sortKey="Lee, J B" sort="Lee, J B" uniqKey="Lee J" first="J. B." last="Lee">J. B. Lee</name>
</author>
<author>
<name sortKey="Kim, Y" sort="Kim, Y" uniqKey="Kim Y" first="Y." last="Kim">Y. Kim</name>
</author>
<author>
<name sortKey="Jung, H C" sort="Jung, H C" uniqKey="Jung H" first="H. C." last="Jung">H. C. Jung</name>
</author>
<author>
<name sortKey="Lee, K" sort="Lee, K" uniqKey="Lee K" first="K." last="Lee">K. Lee</name>
</author>
<author>
<name sortKey="Kim, J C" sort="Kim, J C" uniqKey="Kim J" first="J. C." last="Kim">J. C. Kim</name>
</author>
<author>
<name sortKey="Seo, J T" sort="Seo, J T" uniqKey="Seo J" first="J. T." last="Seo">J. T. Seo</name>
</author>
<author>
<name sortKey="Paick, J" sort="Paick, J" uniqKey="Paick J" first="J." last="Paick">J. Paick</name>
</author>
<author>
<name sortKey="Kim, H" sort="Kim, H" uniqKey="Kim H" first="H." last="Kim">H. Kim</name>
</author>
<author>
<name sortKey="Na, Y G" sort="Na, Y G" uniqKey="Na Y" first="Y. G." last="Na">Y. G. Na</name>
</author>
<author>
<name sortKey="Lee, J G" sort="Lee, J G" uniqKey="Lee J" first="J. G." last="Lee">J. G. Lee</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:09A500C4C70E8A462DC009A9C386CA27B81C751D</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1111/j.1742-1241.2008.01898.x</idno>
<idno type="url">https://api.istex.fr/document/09A500C4C70E8A462DC009A9C386CA27B81C751D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001D65</idno>
<idno type="wicri:Area/Istex/Curation">001D65</idno>
<idno type="wicri:Area/Istex/Checkpoint">000489</idno>
<idno type="wicri:doubleKey">1368-5031:2008:Choo M:efficacy:and:safety</idno>
<idno type="wicri:Area/Main/Merge">001489</idno>
<idno type="wicri:Area/Main/Curation">001469</idno>
<idno type="wicri:Area/Main/Exploration">001469</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double‐blind, multicentre study</title>
<author>
<name sortKey="Choo, M" sort="Choo, M" uniqKey="Choo M" first="M." last="Choo">M. Choo</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul</wicri:regionArea>
<placeName>
<settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lee, J Z" sort="Lee, J Z" uniqKey="Lee J" first="J. Z." last="Lee">J. Z. Lee</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, College of Medicine, Pusan National University, Busan</wicri:regionArea>
<wicri:noRegion>Busan</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lee, J B" sort="Lee, J B" uniqKey="Lee J" first="J. B." last="Lee">J. B. Lee</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, National Medical Center, Seoul</wicri:regionArea>
<placeName>
<settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kim, Y" sort="Kim, Y" uniqKey="Kim Y" first="Y." last="Kim">Y. Kim</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, Soonchunhyang University Bucheon Hospital, Bucheon</wicri:regionArea>
<wicri:noRegion>Bucheon</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Jung, H C" sort="Jung, H C" uniqKey="Jung H" first="H. C." last="Jung">H. C. Jung</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, Yeungnam University Hospital, Daegu</wicri:regionArea>
<wicri:noRegion>Daegu</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lee, K" sort="Lee, K" uniqKey="Lee K" first="K." last="Lee">K. Lee</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea>
<placeName>
<settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kim, J C" sort="Kim, J C" uniqKey="Kim J" first="J. C." last="Kim">J. C. Kim</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, College of Medicine, The Catholic University of Korea, Seoul</wicri:regionArea>
<placeName>
<settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Seo, J T" sort="Seo, J T" uniqKey="Seo J" first="J. T." last="Seo">J. T. Seo</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, Jeil Hospital, Kwandong University College of Medicine, Seoul</wicri:regionArea>
<placeName>
<settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Paick, J" sort="Paick, J" uniqKey="Paick J" first="J." last="Paick">J. Paick</name>
<affiliation>
<wicri:noCountry code="subField">Seoul Korea</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Kim, H" sort="Kim, H" uniqKey="Kim H" first="H." last="Kim">H. Kim</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, Dankook University College of Medicine, Cheonan</wicri:regionArea>
<wicri:noRegion>Cheonan</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Na, Y G" sort="Na, Y G" uniqKey="Na Y" first="Y. G." last="Na">Y. G. Na</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, Chungnam National University College of Medicine, Daejeon</wicri:regionArea>
<wicri:noRegion>Daejeon</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lee, J G" sort="Lee, J G" uniqKey="Lee J" first="J. G." last="Lee">J. G. Lee</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Urology, College of Medicine, Korea University, Seoul</wicri:regionArea>
<placeName>
<settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">International Journal of Clinical Practice</title>
<idno type="ISSN">1368-5031</idno>
<idno type="eISSN">1742-1241</idno>
<imprint>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2008-11">2008-11</date>
<biblScope unit="volume">62</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1675">1675</biblScope>
<biblScope unit="page" to="1683">1683</biblScope>
</imprint>
<idno type="ISSN">1368-5031</idno>
</series>
<idno type="istex">09A500C4C70E8A462DC009A9C386CA27B81C751D</idno>
<idno type="DOI">10.1111/j.1742-1241.2008.01898.x</idno>
<idno type="ArticleID">IJCP1898</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1368-5031</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Purpose:  We assessed the efficacy and safety of solifenacin compared with tolterodine for treatment of overactive bladder (OAB) in Korean patients. Materials and methods:  The study was randomised, double‐blind, tolterodine‐controlled trial in Korea. Patients had average frequency of ≥ 8 voids per 24 h and episodes of urgency or urgency incontinence ≥ 3 during 3‐day voiding diary period. Patients were randomised to 12‐week double‐blind treatment with either tolterodine immediate release (IR) 2 mg twice daily (TOL4) or solifenacin 5 mg (SOL5) or 10 mg (SOL10) once daily. The outcome measure was mean change in daily micturition frequency, volume, daily frequency of urgency incontinence, urgency and nocturia from baseline to week 12. Quality of life was assessed using the King’s Health Questionnaire. Results:  A total of 357 were randomised and 329 were evaluated for efficacy. All voiding parameters recorded in micturition diary improved after treatment in all three groups. Mean changes in volume voided were 19.30 ml (26.69%) in TOL4, 30.37 ml (25.89%) in SOL5 and 37.12 ml (33.36%) in SOL10 group (p = 0.03). Speed of onset of SOL10 efficacy on urgency incontinence was faster than that of SOL5 and TOL4. Quality of life improved in all three groups. Dry mouth was the most common adverse event; its incidence was the lowest in SOL5 group (7.63%, compared with 19.49% and 18.64% in SOL10 and TOL4 groups respectively). Conclusions:  Solifenacin succinate 5 and 10 mg once daily improve OAB symptoms with acceptable tolerability levels compared with tolterodine IR 4 mg. Solifenacin 5 mg is a recommended starting dose in Korean patients with OAB.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Corée du Sud</li>
</country>
<settlement>
<li>Séoul</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Paick, J" sort="Paick, J" uniqKey="Paick J" first="J." last="Paick">J. Paick</name>
</noCountry>
<country name="Corée du Sud">
<noRegion>
<name sortKey="Choo, M" sort="Choo, M" uniqKey="Choo M" first="M." last="Choo">M. Choo</name>
</noRegion>
<name sortKey="Jung, H C" sort="Jung, H C" uniqKey="Jung H" first="H. C." last="Jung">H. C. Jung</name>
<name sortKey="Kim, H" sort="Kim, H" uniqKey="Kim H" first="H." last="Kim">H. Kim</name>
<name sortKey="Kim, J C" sort="Kim, J C" uniqKey="Kim J" first="J. C." last="Kim">J. C. Kim</name>
<name sortKey="Kim, Y" sort="Kim, Y" uniqKey="Kim Y" first="Y." last="Kim">Y. Kim</name>
<name sortKey="Lee, J B" sort="Lee, J B" uniqKey="Lee J" first="J. B." last="Lee">J. B. Lee</name>
<name sortKey="Lee, J G" sort="Lee, J G" uniqKey="Lee J" first="J. G." last="Lee">J. G. Lee</name>
<name sortKey="Lee, J Z" sort="Lee, J Z" uniqKey="Lee J" first="J. Z." last="Lee">J. Z. Lee</name>
<name sortKey="Lee, K" sort="Lee, K" uniqKey="Lee K" first="K." last="Lee">K. Lee</name>
<name sortKey="Na, Y G" sort="Na, Y G" uniqKey="Na Y" first="Y. G." last="Na">Y. G. Na</name>
<name sortKey="Seo, J T" sort="Seo, J T" uniqKey="Seo J" first="J. T." last="Seo">J. T. Seo</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/corpus/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001469 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:09A500C4C70E8A462DC009A9C386CA27B81C751D
   |texte=   Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double‐blind, multicentre study
}}

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Wed Aug 16 22:49:51 2017